Compare TKLF & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKLF | ASBP |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 15.0M |
| IPO Year | 2022 | N/A |
| Metric | TKLF | ASBP |
|---|---|---|
| Price | $3.04 | $0.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.3K | ★ 17.6M |
| Earning Date | 12-19-2025 | 11-14-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $302,537,158.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.92 | ★ N/A |
| Revenue Growth | ★ 37.82 | N/A |
| 52 Week Low | $2.10 | $0.07 |
| 52 Week High | $4.32 | $15.80 |
| Indicator | TKLF | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 54.29 |
| Support Level | $2.74 | $0.09 |
| Resistance Level | $3.14 | $0.14 |
| Average True Range (ATR) | 0.21 | 0.01 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 91.13 | 84.40 |
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.